
ALT **Scientists Are Now Testing DNA Repair Technology Directly Inside the Human Body! What if doctors could correct a disease-causing genetic mistake without removing a patient's cells or performing a transplant? That possibility is moving closer to reality. In 2025, researchers used a personalized CRISPR base-editing treatment to target a genetic defect in an infant with a rare, life-threatening liver disease called CPS1 deficiency. Now, another milestone has arrived. In October 2026, the first patient received an experimental prime-editing treatment in a Phase 1/2 clinical trial for Wilson disease, a genetic condition that causes dangerous copper buildup in the body. The treatment is designed to deliver molecular editing tools through a single intravenous infusion and correct the faulty DNA inside liver cells.

















